Corporate Information – Page 21 – Alligator Bioscience

2019-11-06

Alligator Bioscience: ATOR-1017 Induces Long-Lasting Immunity – New Preclinical Data to be presented at SITC 34th Annual Meeting

Lund, Sweden, November 6, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the company will present new preclinic ...

2019-08-20

Regulatory

Lund, Sweden, August 20, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that a license agreement has been reached wi ...

2019-07-31

Regulatory

Lund, Sweden, July 31, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that it has regained exclusive, worldwide righ ...

2019-06-18

Lund, Sweden, June 18, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2019-06-18

Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...

2019-06-14

Two Alligator projects presented at ASCO. "The American Society of Clinical Oncology (ASCO) is a professional organization for oncologis ...

2019-05-16

Lund, Sweden, May 16, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the outline of the ongoing Phase I study w ...

2019-05-15

Regulatory

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will prese ...

2019-05-09

Lund, Sweden, May 9, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutical ...